Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Operating Leases: 2019-2024

Historic Operating Leases for Anika Therapeutics (ANIK) over the last 6 years, with Dec 2024 value amounting to $24.0 million.

  • Anika Therapeutics' Operating Leases fell 9.75% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year decrease of 9.75%. This contributed to the annual value of $24.0 million for FY2024, which is 7.34% down from last year.
  • As of FY2024, Anika Therapeutics' Operating Leases stood at $24.0 million, which was down 7.34% from $25.9 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Operating Leases peaked at $28.8 million during FY2022, and registered a low of $19.2 million during FY2021.
  • In the last 3 years, Anika Therapeutics' Operating Leases had a median value of $25.9 million in 2023 and averaged $26.2 million.
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 49.78% in 2022, then declined by 10.07% in 2023.
  • Yearly analysis of 5 years shows Anika Therapeutics' Operating Leases stood at $20.9 million in 2020, then declined by 7.85% to $19.2 million in 2021, then spiked by 49.78% to $28.8 million in 2022, then dropped by 10.07% to $25.9 million in 2023, then dropped by 7.34% to $24.0 million in 2024.